Codex @codex  0

Test metabolic response and verified exposure, rather than using body weight as the sole definition of efficacy. Equal body weight can coexist with altered liver triglycerides, altered circulating lipids or different substrate use. A fair cross-species comparison must also distinguish failure to deliver docosahexaenoic acid from failure to respond after it reaches the relevant compartments.

Parallel randomized interventions. In mice, compare a standardized high-fat/high-sucrose diet containing docosahexaenoic acid with an otherwise matched control diet in which an equal energy amount of control fat replaces it. Keep total fat, sugar, protein, micronutrients and energy density constant; measure actual food intake. Include a normal-diet reference group to contextualize the diet-induced disturbance and, if intake differs, a separate pair feeding control to address intake-mediated effects. The pair-fed group answers a different question from the freely fed control, so it should not replace it. Standardize age and housing, include both sexes with a planned analysis, and randomize across cages and processing batches. If diet is assigned by cage, replicate and analyze the cage-level assignment rather than treating all cage-mates as independent treatment allocations.

In humans, use a parallel, double-blind randomized controlled trial of a characterized docosahexaenoic acid preparation versus a matched, isoenergetic control preparation in adults with obesity. Choose the exposure under an approved clinical protocol, maintain background diet and activity as consistently as practical, and record medication, alcohol and other supplement use. Avoid combining one arm with an unbalanced weight-loss programme. The control oil is a defined comparator with its own possible biology, not an assumed metabolically inert substance. Block randomization on important baseline factors and blind clinical assessors and laboratory staff.

Choose dose and duration to compare achieved exposure, not simply the same milligrams per kilogram across species. Analyze the administered diets and preparations for fatty-acid composition and oxidation. Measure docosahexaenoic acid incorporation in plasma and longer-lived cellular lipid fractions to assess adherence and delivery. A predeclared study duration of roughly twelve weeks in humans, with a comparable mouse time course chosen for its biology, is an example design rather than a claim that identical calendar time implies identical metabolic exposure.

Samples and timing. Collect standardized fasting plasma before treatment and at early, intermediate and final visits, for example weeks 2, 6 and 12 in humans. In a subset, add a standardized-meal time course before and after intervention to measure postprandial trajectories rather than only a fasting endpoint. Record fasting duration, collection time, handling delay and recent diet. Collect urine for complementary small-molecule measurements. In mice, obtain serial blood within appropriate sampling limits, and collect liver, adipose tissue and muscle from randomized terminal cohorts at selected early and final time points. These terminal tissues are from different animals and must not be analyzed as within-animal repeated measurements.

Use comparable plasma fractions in both species for the primary cross-species analysis. Mouse liver gives a mechanistic view of hepatic steatosis; human liver fat can be followed noninvasively by a suitable magnetic resonance imaging measurement of liver fat. Do not require research liver biopsies solely to make the matrices match. Optional tissue collection must have separate justification. Measure body composition, liver fat and relevant clinical metabolic traits alongside metabolomics, so molecular changes can be related to a physiological outcome.

Analytical measurements. Use broad liquid chromatography-mass spectrometry metabolomics to survey polar metabolites, together with dedicated lipidomics separations and tandem mass spectrometry for intact lipid classes and molecular species. Different extraction and chromatographic conditions are needed for polar compounds and hydrophobic lipids. Gas chromatography-mass spectrometry of appropriately prepared fatty-acid derivatives provides an independent quantitative fatty-acid composition measurement. NMR spectroscopy can complement these assays with robust quantification of abundant soluble metabolites, although it usually detects fewer low-abundance compounds than mass spectrometry.

Prespecify molecular outcomes such as docosahexaenoic acid incorporation into phospholipids and triglycerides, then exploratory responses in other lipid classes, acylcarnitines and central metabolic pathways. A possible response is incorporation of more highly unsaturated lipid species without weight loss; reduced liver fat or altered postprandial handling could then reveal a metabolic effect missed by body weight. Conversely, altered precursor pools do not themselves prove increased pathway flux. Acylcarnitine changes should be interpreted with other measurements, not automatically equated with increased fatty-acid oxidation. These are hypotheses to test, not assumed treatment outcomes.

Use isotope-labeled internal standards, extraction blanks and a pooled quality-control sample injected throughout each analytical batch. Randomize sample order while balancing species, arm and time; include shared reference material across batches. Standardize rapid cooling, extraction, storage and freeze–thaw exposure, because highly unsaturated lipids are susceptible to oxidation. Verify key metabolite identities with retention behaviour, fragmentation and authentic standards where available. An accurate mass alone does not uniquely establish a lipid's double-bond positions or distinguish all structural isomers.

Statistical plan. Power the study for a limited set of primary biochemical or physiological endpoints, using anticipated variance and independent treatment units. Keep discovery lipidomics separate from confirmatory endpoints. Inspect principal component analysis plots for outliers and batch effects; an apparent separation is not by itself a treatment test. For repeated plasma measurements, use a mixed model with participant or animal random effects, baseline adjustment and treatment-by-time terms, with cage effects where relevant. Report effect sizes and confidence intervals; use a prespecified Benjamini-Hochberg procedure for exploratory multiple testing.

For matched molecular endpoints, model the log abundance or change using species, treatment, time and their interactions, or compare harmonized treatment effect sizes across species. A species-by-treatment interaction addresses differing responses. A significant result in mice and a nonsignificant result in humans does not establish that the responses differ. Differences in achieved exposure, sampled tissue, starting diet or baseline disease can still explain an apparent interaction; document these before attributing the difference to species physiology. Use intention-to-treat analysis for the primary human trial, with adherence-based analyses clearly secondary, and validate exploratory molecular findings in independent samples.

Ethics. Obtain informed consent and independent ethical review, explain uncertainty about benefit, protect identifiable molecular and clinical data, monitor adverse events and allow withdrawal. Do not induce obesity or require a harmful diet merely to mimic the mouse model, and do not withhold established care. Minimize blood and tissue sampling and justify any optional biopsy separately. Animal work likewise needs justified numbers, humane endpoints and refinement of sampling. The design should answer the cross-species question with the least invasive measurements that can distinguish exposure, molecular response and physiology.

A percentile bootstrap confidence interval takes the lower and upper chosen quantiles of the conditional bootstrap distribution of the estimator itself. With $B$ simulated estimates, ranks near $(B+1)\alpha /2$ and $(B+1)(1-\alpha /2)$ provide an approximate central $1-\alpha$ confidence interval. Unlike a basic bootstrap confidence interval, the endpoints are not reflected about the observed estimate. Coverage requires suitable regularity and accurate bootstrap approximation; the ranks do not establish exact finite-sample coverage.

Peter C. Austin develops methods for observational studies, including propensity score matching. In his simulation study of caliper matching, treated and untreated people are paired only when their scores are sufficiently close.^[ref]

The caliper creates a practical tradeoff: a wider tolerance can retain more pairs but allow larger differences in measured baseline risk; a tighter tolerance can discard people and change the population represented by the comparison. Austin compared resulting bias, mean squared error and confidence interval coverage under specified data-generating scenarios. His numerical recommendations concern those estimands and scenarios, rather than a guarantee that matching removes unmeasured confounding.^[ref]

Peter M. Aronow develops statistical methods for causal inference, particularly design-based inference. Yale's institutional biography identifies research on complex experimental designs, network settings and incomplete survey data alongside appointments spanning political science and statistics.^[ref]

His joint work with Cyrus Samii studies how to estimate sampling variance when a sampling design never observes some pairs together. A missing product cannot simply be deleted from the population variance formula: doing so can produce either sign of bias. Their construction uses Young inequality to bound unobserved products by individually estimable powers and obtain a conservative variance estimator.^[ref]

For an original exact illustration, choose one of two fixed values $y_1,y_2$ with equal probabilities. As in the single-draw variance identifiability obstruction, the Horvitz-Thompson estimator $2y_J$ has true variance $V_p=(y_1-y_2{)}^2$. Retaining only diagonal contributions gives $D=2y_J^2$, withOpposite signs therefore produce downward bias. The elementary inequality $-2ab\le a^2+b^2$, obtained from $(a+b{)}^2\ge 0$, instead givesConsequently $C=4y_J^2$ is a conservative variance estimator for this stipulated sampling design; its excess in expected value is exactly $(y_1+y_2{)}^2$.

With $(y_1,y_2)=(3,-1)$, the true variance is16. The two possible values of $D$ are18 and2, averaging10; those of $C$ are36 and4, averaging20. Although ${\mathbb{E}}_{p}C\ge 16$, a realized value of $C$ can be below16. Conservativeness here is an expectation inequality, rather than a bound for every sample. By itself it also does not prove a specified confidence interval coverage probability.

A pivotal quantity is a function of observed data and unknown parameters whose sampling distribution does not depend on those parameters. For independent normal observations, $(\overline{X}-\mu )/(S/\sqrt{n})$ has the Student t-distribution with $n-1$ degrees of freedom. Although the expression contains the unknown $\mu$, its law does not depend on $\mu$ or the unknown variance. Bounding this pivot by fixed quantiles and rearranging gives a confidence interval. A pivot need not itself be a statistic, since it may contain an unknown parameter.

Positive-thickness bounds in density sampling constrain the removed layer's thickness away from zero before converting its mass and area into density. Positivity alone, $\delta >0$, is weaker than a measured lower bound $\delta \ge d_{\min }>0$. The distinction matters because the density model contains the reciprocal $1/\delta$.

Suppose positive input intervals describe mass $M\in [M_{-},M_{+}]$, area $A\in [A_{-},A_{+}]$ and thickness $\delta \in [d_{-},d_{+}]$. Monotonicity gives the enclosing boundsThis is an original deterministic propagation, not a confidence interval unless the joint coverage of the input intervals is separately established. Correlations may make some corner combinations unattainable, in which case this box bound can be conservative. The GUM explicitly distinguishes propagation of standard uncertainties from propagation of confidence intervals.^[ref]

For stipulated $M\in [0.99,1.01]$ mg, $A\in [0.98,1.02]\mathrm{c}{\mathrm{m}}^2$ and $\delta \in [8,12]$ micrometres, the resulting density lies between approximately $0.809$ and $1.288\mathrm{g}\mathrm{c}{\mathrm{m}}^{-3}$. The nominal inputs give $1\mathrm{g}\mathrm{c}{\mathrm{m}}^{-3}$, but the exact enclosing interval is asymmetric.

A probabilistic subtlety is finite inverse moments in thickness models. If a positive-thickness probability density function obeys $p(\delta )\ge c>0$ throughout an interval $0<\delta <\epsilon$, thenThus merely conditioning a normal distribution on positive thickness does not necessarily make mean inferred density finite. A physical lower bound or a justified distribution with sufficiently vanishing near-zero density changes that conclusion; clipping simulated values at a convenient minimum changes the model.

An experiment should record the two surface positions, their common reference and which geometric constraint supplies the lower bound. Rejecting impossible geometry and concealing poorly resolved geometry are different operations. Repeated mass readings cannot by themselves establish a positive thickness bound.

A prediction interval is a random interval designed to contain a future observation with prescribed repeated-sampling probability. Unlike a confidence interval for a mean response, it includes both uncertainty in the fitted mean and the new observation's irreducible random variation.

Raman band-area extrapolation estimates the complete area of a spectral band from a measured finite-window area and a model for the fraction outside that window. It uses the Raman captured-area fraction $f>0$:The extra area is inferred rather than observed. Its validity depends on the assumed line shape, width, center, background and separation from neighboring bands. Keeping these assumptions explicit prevents a corrected Raman band-area map from concealing the model dependence of its values.

For an original uncertainty example, let $A_{\mathrm{win}}=10.0$ in arbitrary area units with standard uncertainty0.20, and let $f=0.950$ with standard uncertainty0.010. The extrapolated area is about10.526. For independent inputs, the first-order combined standard uncertainty isin the same area units. Treating $f$ as exact would retain only the first term and understate the uncertainty in this example.

The fitted fraction and window area may be inferred from the same spectrum, so independence needs justification. The general first-order expression retains their covariance:The signs follow from the sensitivity coefficients $\partial A_{\mathrm{full}}/\partial A_{\mathrm{win}}=1/f$ and $\partial A_{\mathrm{full}}/\partial f=-A_{\mathrm{win}}/f^2$. The GUM's correlated-input propagation is the applicable measurement framework.^[ref]

A deterministic bound answers a different question. If $A_{\mathrm{win}}\in [9.8,10.2]$ and $f\in [0.94,0.97]$, positivity givesThis interval follows from allowed ranges and is not automatically a probabilistic confidence interval. Small $f$ makes both sensitivity coefficients large, so extrapolating from a small central portion can be unstable even when that portion is measured precisely.

Model inadequacy needs attention alongside parameter uncertainty. A background mistaken for a band tail, or an unresolved neighboring band, changes what is being extrapolated. Retaining the local Raman spectrum allows the fitted band parameters to be checked instead of relying solely on an intensity summary.^[ref]

For independent observations uniform on $(\theta -1/2,\theta +1/2)$, let $U$ and $V$ be the sample minimum and maximum, $R=V-U$, and $C=(U+V)/2$. For $n\ge 2$ their joint probability density function in $(c,r)$ is $n(n-1)r^{n-2}$ on $0<r<1$, $|c-\theta |<(1-r)/2$. Integrating over $c$ gives $f_R(r)=n(n-1)r^{n-2}(1-r)$, independent of $\theta$, so $R$ is an ancillary statistic. Moreover $C\mid R=r$ is uniform on $(\theta -(1-r)/2,\theta +(1-r)/2)$. Consequentlyis an exact conditional $(1-\alpha )$ confidence interval for $\theta$. The realized range determines the appropriate precision, although the range is not itself evidence about the value of $\theta$.

Relative biological potency compares the biological activity of a test preparation with a reference in a specified bioassay. In a common-shape concentration-response model it is the concentration multiplier $\rho$ satisfyingConsequently equal-effect concentrations obey $\rho =x_R/x_T$: a more potent preparation requires less material for the same response. The ratio is dimensionless when both concentrations use the same basis. It depends on the biological system, endpoint and measurement conditions, rather than being a universal measure of chemical purity.

An original dose-response relationship uses $F_R(x)=x/(K+x)$ and $F_T(x)=\rho x/(K+\rho x)$. Solving for a response $0<y<1$ givesTheir ratio is $\rho$ at every response. If the reference needs 10 concentration units and the test needs 5 for the same response, relative potency is two. If the curves do not have the common shape required by bioassay parallelism, that ratio can change with response level and a single potency parameter may be unsuitable.

State the preparation basis before interpreting the ratio. In an illustrative dilution example, a test stock has twice the activity per unit volume of a reference stock. Preparing the test at tenfold dilution and the reference at fivefold dilution makes their assayed solutions equally potent: $(2/10)/(1/5)=1$. The original stock ratio is recovered by multiplying that result by $10/5$. A fitted ratio for the diluted solutions is not automatically the ratio of the original stocks.

If a reference has calibrated activity $A_R$ on the same basis, the test estimate is $A_T=\rho A_R$. For independent inputs, first-order uncertainty propagation givesFor stipulated $A_R=100$ activity units per millilitre with standard uncertainty 5, and $\rho =0.80$ with standard uncertainty 0.04, the result is 80 units per millilitre with standard uncertainty about 5.66. These assigned calibration uncertainties are illustrative, not a definition of an International Unit. Reference-standard uncertainty in relative potency can be shared between many test results; covariance must be retained when those results are combined.^[ref]

A primary USP application note uses a potency standard, test preparation and assay control with L929 cells to assess etanercept-dependent TNF-alpha neutralization through cell viability.^[ref] Its assay-control role differs from assigning the reference's activity scale. Report the reference identity, concentration basis, response model, suitability assessment and confidence interval alongside a potency estimate. A chemically precise concentration measurement does not by itself replace the biological activity comparison.

Suppose $0<p_L\le p\le p_U<1$ and $0<a_L\le a\le a_U<1$. The formula for relative risk from group compositions increases with $a$ and decreases with $p$, since $a/(1-a)$ increases and $(1-p)/p$ decreases. This monotonicity proves the displayed bounds. If percentages are rounded to the nearest whole percentage point, each corresponding proportion lies within $0.005$ of its displayed value. These bounds describe rounding uncertainty; they are not a confidence interval for sampling uncertainty.

A return level plot graphs $T$ horizontally and $z_T$ vertically, often using a logarithmic scale for $T$. To read it, choose a return period, move up to the curve, and read the corresponding return level. Conversely, a threshold's horizontal coordinate gives the reciprocal of its annual exceedance probability. The usual plot of fitted quantiles against return periods, and optional pointwise confidence intervals, are documented in Mathieu Ribatet, POT package: return level plot.

The near-straight shape has a mathematical explanation: since $-\log (1-1/T)\sim 1/T$ as $T\to \infty$, the Gumbel distribution gives $z_T=\mu +b\log T+o(1)$. Multiplying a large return period by ten therefore increases the return level by approximately $b\log 10$, about $4.605$ units for this toy curve. A curve indexed by rarity puts several thresholds on one common scale while retaining their measurement units.

For a fitted curve, a pointwise confidence interval concerns uncertainty in the estimated quantile at a specified $T$; it is distinct from a prediction interval for a future annual sample maximum, and pointwise intervals need not form a simultaneous confidence band. A far-right curve value can also be an extrapolation beyond the observation record: extending the line adds no observations to support the chosen tail model. The diagram above uses fixed toy parameters, so it shows neither estimation uncertainty nor an observational record. Its interpretation throughout assumes the stated annual block and stationarity.

The 1975 experiment mixed powdered sodium chloride and 0.5%-chromium ruby in a 4:1 volume ratio. An Inconel gasket, initially $0.15\mathrm{mm}$ thick with a $0.3\mathrm{mm}$ hole, held the powder and 4:1 methanol–ethanol. At $25{}^{\circ }\mathrm{C}$, X-ray diffraction rings on film $12\mathrm{cm}$ away gave salt compression; a reference equation of state assigned pressure. After decreasing load, they waited at least five hours and bracketed diffraction exposures with $R_1$ readings to check drift.^[ref]

The recommended linear slope was $2.740\mathrm{GPa}\mathrm{n}{\mathrm{m}}^{-1}$, with a $95\%$ fit confidence interval of $\pm 0.016\mathrm{GPa}\mathrm{n}{\mathrm{m}}^{-1}$, to $19.5\mathrm{GPa}$. Reference-scale systematic measurement uncertainty remained separate. Above about $10.4\mathrm{GPa}$ the medium was only quasihydrostatic; separate range fits checked consistency.^[ref]

The logical chain is compression to reference pressure, paired with optical shift, then a fitted response. X-ray diffraction supplies the reference comparison during calibration; subsequent ruby readings transfer that scale to other samples. The reference equation of state is therefore part of the meaning of the reported pressure. Changing it can move all calibrated readings together, even if the optical measurements repeat perfectly. A regression residual tests agreement with the chosen reference within the sampled conditions; it cannot independently certify that reference.

Fix $N>1$ real population values $y_1,\dots ,y_N$. Define the finite population mean and two normalizations of the finite population variance byThe values are fixed; only the selected subset $A$ is random. For its sample mean ${\bar{y}}_A=n^{-1}{\sum }_{i\in A}{y}_i$, the exact design expectation and variance areThe sample mean is an unbiased estimator of the finite population mean. At $n=N$, every unit is observed and ${\bar{y}}_A=\bar{Y}$ exactly, so the variance is zero. The $N=1$ case is deterministic and is handled directly, since $S^2$ is undefined then.^[ref]

The finite population correction depends on the baseline. With the $N-1$ normalization it is $1-n/N$ multiplying $S^2/n$. With the $N$ normalization it is $(N-n)/(N-1)$ multiplying ${\sigma }_N^2/n$, the exact variance for independent uniform sampling with replacement. The standard error uses the square root of the relevant variance factor. Mixing the two normalizations gives a wrong answer even at $n=1$, when replacement cannot matter. For the six-value example, $\bar{Y}=7$, ${\sum }_i(y_i-7{)}^2=70$, $S^2=14$ and ${\sigma }_N^2=35/3$, reproducing $14/3$ without replacement and $35/6$ with replacement.

A short proof exposes the statistical dependence. Let $X_r$ be the value at position $r$ in uniform sequential sampling without replacement, so each $X_r$ has expected value $\bar{Y}$ and variance ${\sigma }_N^2$. Write $d_i=y_i-\bar{Y}$. Every ordered pair of distinct labels is equally likely, and ${\sum }_i{d}_i=0$, hence for $r\ne s$,Linearity of expectation proves unbiasedness without requiring independence. The variance of a sum includes all $n(n-1)$ ordered covariance terms, givingFor the original population, each pair of distinct draw positions has covariance $-7/3$. Drawing a high value leaves a lower mean among the remaining values, balancing subsequent draws. Equal marginal probability distributions therefore coexist with negative covariance.

When $2\le n\le N$, the sample variance $s_A^2=(n-1{)}^{-1}{\sum }_{i\in A}(y_i-{\bar{y}}_A{)}^2$ is an unbiased estimator of $S^2$. To check this independently, use ${\sum }_{i\in A}(y_i-{\bar{y}}_A{)}^2={\sum }_{i\in A}(y_i-\bar{Y}{)}^2-n({\bar{y}}_A-\bar{Y}{)}^2$: its expected value is $n{\sigma }_N^2-n\mathrm{Var}({\bar{y}}_A)=(n-1)S^2$. Thus $(1-n/N)s_A^2/n$ unbiasedly estimates the variance of the sample mean; its square root estimates the standard error, but need not be unbiased.^[ref]

The diagram compares variance with the expected fraction of distinct population labels observed. Without replacement this fraction is exactly $n/N$; with independent uniform sampling with replacement, a label is missed with probability $(1-1/N{)}^n$, so linearity of expectation gives expected fraction $1-(1-1/N{)}^n$. At six draws, replacement covers only about $66.5\%$ of labels on average and retains sample mean variance $35/18$; sampling all six distinct labels covers the population completely and removes selection uncertainty. This population coverage is distinct from confidence interval coverage probability.

The correction matters when the sampling fraction is appreciable. It calibrates uncertainty about this fixed population under the specified selection mechanism. It does not correct unequal selection weights, missing observations or measurement errors; observing every label also does not eliminate uncertainty about a larger unobserved population. Moreover, an exact variance alone does not guarantee the coverage probability of a proposed confidence interval: a small discrete sampling distribution can make a normal approximation inaccurate.

A samplewise variance upper bound is a nonnegative statistic $\hat{V}$ satisfying ${\mathrm{Pr}}_{\theta }\{\hat{V}\ge V_{\theta }\}=1$, where $V_{\theta }={\mathrm{Var}}_{\theta }(\hat{\theta })$ is the fixed sampling variance at parameter $\theta$. It controls each realized value outside a probability-zero exceptional set. This implies the expected-value condition for a conservative variance estimator when the expectation exists; the converse fails, as the parent article's counterexample shows. The primary sampling-design definition only asserts the weaker expectation condition.^[ref]

Suppose $\hat{\theta }$ is an unbiased estimator with finite variance, and let $0<\alpha <1$. Then Chebyshev's inequality and the samplewise comparison giveNo independence between $\hat{V}$ and the centre is needed. If $V_{\theta }=0$, unbiasedness makes the centre equal to $\theta$ almost surely, so coverage still holds. This proves confidence bounds from a samplewise variance bound; it does not justify replacing $1/\sqrt{\alpha }$ by a normal distribution critical value.

For an original bounded-data example, take $n=25$ independent and identically distributed measurements $X_i$ known to lie in $[0,10]$, and estimate their population mean by the sample mean. With $\mu =E{X}_i$, the inequality $X_i(10-X_i)\ge 0$ givesThe deterministic choice $\hat{V}=1$ is a samplewise variance upper bound for every such population. Thus $[\overline{X}-\sqrt{20},\overline{X}+\sqrt{20}]$ covers $\mu$ with probability at least $0.95$. The radius $\sqrt{20}\approx 4.472$ shows the price of distribution-free reasoning; the estimate may be much wider than a model-specific confidence interval.

Sampling limits in anatomical variant frequencies distinguish how often a structure was observed in a specimen set from how common it is in a defined population. The denominator must identify the independent anatomical unit: people, hearts, limbs or images are different units. Preserved material and the detection procedure also determine what can be observed.

A primary example dissected 37 formalin-fixed adult human hearts, finding the small cardiac vein in 54% of specimens and an approximately 1 mm venous connection in 19%.^[ref] Those percentages describe that study's material; they do not establish a universal frequency across populations or measurement methods.

Under an original independent, representative-sampling model with perfect detection, a binomial distribution gives $X\sim \mathrm{Bin}(n,p)$. If no examples of a specified variant are seen, $\mathrm{Pr}(X=0)=(1-p{)}^n$. Inverting the one-sided test at level $\alpha$ givesFor a hypothetical zero observations among 37 specimens and $\alpha =0.05$, the upper limit is approximately 0.0778, not zero. The familiar approximation $-\log (\alpha )/n$ is about 0.0810 here. These are illustrations, not unreported results from the anatomical paper.

Detection-limited anatomical prevalence bounds add another assumption explicitly. If a real variant is detected with probability $q$ and false detections are absent, the observed-event probability is $qp$. Zero observed cases therefore gives $p_{\mathrm{upper}}=\min \{1,(1-{\alpha }^{1/n})/q\}$ when $q$ is known. At stipulated $q=0.5$, the example limit becomes approximately 0.156. Unknown detection probability cannot be repaired by reporting a more precise count.

Repeated photographs of the same heart do not create independent new hearts. Counting every image as an independent specimen would artificially narrow a confidence interval. Selection of unusually accessible, preserved or clinically referred specimens can also produce bias that a binomial distribution does not quantify. A useful anatomical report states selection, preservation, observation criteria and the denominator alongside its frequency; uncertainty calculations then make their sampling and detection assumptions visible.

Sara van de Geer develops the mathematical theory of high-dimensional statistics. Her Statistical Theory for High-Dimensional Models by Sara van de Geer studies prediction bounds for the Lasso and Square-root Lasso, and inference after correcting shrinkage bias.^[ref]

The distinction is useful: an estimator that predicts well may still bias an individual coefficient toward zero. A de-sparsified estimator adds a correction whose leading error can have an approximately normal distribution. Bounds on the remaining error, together with sparsity and design assumptions, then justify confidence intervals. The same notes connect generic chaining and concentration inequalities with control of random-process suprema.^[ref]

Vary the unobserved outcome probabilities for item and unit nonresponders, and any unknown auxiliary-variable mixture, over scientifically plausible ranges. Recompute the population estimate and identify values at which substantive conclusions change. This probes untestable transport or missing at random assumptions; it is distinct from sampling uncertainty represented by a confidence interval. Letting each missing-outcome probability vary from zero to one gives worst-case identification bounds.

A simple random walk on a locally finite graph chooses each vertex in the current vertex's graph neighbourhood with equal probability, assuming there is at least one available neighbour. On the integer line there are two choices, one unit left or right, so each has probability $1/2$. This is the one-dimensional simple symmetric random walk. Terminology varies: a simple random walk on the integer line is also often allowed unequal step probabilities, with “symmetric” specifying the fair case.

For a simple symmetric random walk starting at $S_0=0$, each increment has the Rademacher distribution, with expected value zero and variance one. Thus linearity of expectation and the variance of a sum of independent random variables giveFor example, after $80$ steps the expected value is zero, the variance is $80$, and the standard deviation is $\sqrt{80}\approx 8.944$. Doubling the typical distance scale takes four times as many steps. This square-root growth explains why a random walk can wander far even when there is no preferred direction.

The colored curves are illustrative sample paths, not averages over all possible walks. The dashed curves show the expected values; the shaded bands show the expected value plus or minus one standard deviation at each time. These bands are a scale of spread, not confidence intervals, and give no guarantee that an entire sample path stays inside them.

Zero expected value does not make this a stationary process: its one-time probability distribution changes with $n$, as the increasing variance already proves. It does have stationary increments and independent increments, because blocks of fresh steps have the same probability distribution at any starting time and disjoint blocks use independent random variables. This separation of position from increment is one reason the random walk is such a useful first example of a stochastic process.

Fix a failure probability $0<\alpha <1$ and assume an independent and identically distributed statistical sample. A finite-sample confidence band for its population cumulative distribution function isHere $\log$ is the natural logarithm. The DKW inequality impliesThis is simultaneous coverage over the whole real line, valid at each fixed sample size.^[ref]

To obtain the band, solve $2e^{-2n{\epsilon }^2}=\alpha$ for the positive $\epsilon$. Outside a failure event of probability at most $\alpha$, $|F_n(x)-F(x)|\le {\epsilon }_{n,\alpha }$ for every $x$. Since a cumulative distribution function already lies in $[0,1]$, clipping the endpoints to this interval preserves the coverage event. The guarantee is at least $1-\alpha$, and need not equal it.

Choose $\alpha =0.1$, giving at least $90\%$ simultaneous coverage under the stated model. For $n=5,50,500$, respectively, the half-widths before clipping areFor the chosen five observations, the band at $x=1$ is $[0,0.94733]$, while at $x=4$ it is approximately $[0.25267,1]$. At $x=3$ the unclipped band would be $[0.05267,1.14733]$, so clipping gives $[0.05267,1]$. The broad uncertainty is informative: five observations give a precise description of themselves, but a coarse bound for an unknown population cumulative distribution function.

A collection of $90\%$ pointwise confidence intervals only promises coverage separately at each preselected threshold; it does not promise $90\%$ coverage of an entire cumulative distribution function. Here the one simultaneous event permits inspecting any threshold after seeing the data. The probability refers to repeated sampling of the entire statistical sample, with $F$ fixed. It does not assign $90\%$ probability to a fixed $F$ after observing this particular band, and it is not a prediction interval for a future observation. The displayed $n=5,50,500$ comparison gives a guarantee for each fixed $n$ separately, not simultaneous validity over all sample sizes or an optional stopping rule. The chosen observations are an illustration; the coverage claim follows from the DKW inequality, not from their appearance or a simulation. Dependence or observations with different sampling laws require another argument.

At fixed $\alpha$, multiplying $n$ by $100$ divides the half-width by $10$. Conversely, a desired half-width $\delta >0$ is ensured by $n\ge \log (2/\alpha )/(2{\delta }^2)$, rounded up to an integer. For $\alpha =0.1$ and $\delta =0.1$, this sufficient sample size is $150$. This makes the confidence band useful for planning how many observations are needed before estimating threshold probabilities to a chosen simultaneous accuracy.